Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci D. All-cause mortality in 272,186 people hospitalized with atrial fibrillation from 1995 to 2008: a Swedish national long-term case-control study. . Eur Heart J. 2013;34(14):1061–7.
Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Global epidemiology of atrial fibrillation: Global Burden of Disease 2010 study. Circulation. 2014;129(8):837–47.
Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS et al. Trends in the burden of inpatient treatment for atrial fibrillation in South Korea (from 2006 to 2015). heart. 2018;104(24):2010–7.
Kim D, Yang PS, Jang E, Yu HT, Kim TH, Uhm JS et al. 10 on the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation using national health insurance data covering the entire Korean population. Annual national trends. Am Heart J. 2018;202:20–6.
Burdett P, Lip GYH. Atrial fibrillation in the UK: Predicting the costs of an emerging epidemic Recognizing and predicting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clinical Results. 2022;8(2):187–94.
Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, et al. 2018 Korean Atrial Fibrillation Management Guidelines. Korea Circ J. 2018;48(12):1033–80.
Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projection of the number of patients with atrial fibrillation in the European Union from 2000 to 2060. Eur Heart J. 2013;34(35):2746–51.
Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Pastor Cardiol. 2014;11(11):639–54.
Schnabel RB, Sullivan LM, Levy D, Pensina MJ, Massaro JM, D'Agostino RB Sr, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373(9665):739–45.
Alonso A, Krite BP, Aspelund T, Stepas KA, Pensina MJ, Moser CB, et al. A simple risk model predicts the incidence of atrial fibrillation in an ethnically and geographically diverse population: CHARGE-AF Consortium. . J Am Heart Society 2013;2(2):e000102.
Chung MK, Eckhardt LL, Chen LY, Ahmed HM, Gopinathannair R, Joglar JA, et al. Lifestyle and risk factor modifications to reduce atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020;141(16):e750–72.
Lau DH, Nattel S, Kalman JM, Sanders P. Modifiable risk factors and atrial fibrillation. Circulation. 2017;136(6):583–96.
Staerk L, Wang B, Preis SR, Larson MG, Lubitz SA, Ellinor PT, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: A cohort study based on longitudinal data from the Framingham Heart Study. B.M.J. 2018;361:k1453.
Heeringa J, van der Kuip DA, Hoffmann A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation: the Rotterdam Study. Eur Heart J. 2006;27(8):949–53.
Mou L, Norby FL, Chen LY, O'Neal WT, Lewis TT, Loehr LR, et al. Lifetime risk of atrial fibrillation by race and socioeconomic status: the ARIC study (Atherosclerosis Risk in Communities). Circulatory arrhythmia electrophysiology. 2018;11(7):e006350.
Weng LC, Preis SR, Hulme OL, Larson MG, Choi SH, Wang B et al. Genetic predisposition, clinical risk factor burden, and lifetime risk of atrial fibrillation. Circulation. 2018;137(10):1027–38.
Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS et al. Lifetime risk of developing atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110(9):1042–6.
Magnussen C, Niilanen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I Gender differences and similarities in the epidemiology, risk factors, and mortality of atrial fibrillation in other community cohorts: BiomarCarE consortium (Cardiovascular Biomarkers for risk assessment) results. Circulation. 2017;136(17):1588–97.
Chao TF, Liu CJ, Tuan TC, Chen TJ, Hsieh MH, Lip GYH, Chen SA. Lifetime risks, predicted values, and adverse outcomes in Asian atrial fibrillation patients: report from the Taiwan National Atrial Fibrillation Cohort Study. chest. 2018;153(2):453–66.
Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GYH. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. chest. 2015;147(1):109–19.
Volgman AS, Bairy Merz CN, Benjamin EJ, Curtis AB, Fang MC, Lindley KJ, et al. Gender and racial/ethnic differences in atrial fibrillation. J Am Col Cardiol. 2019;74(22):2812–5.
Elizabeth MH, Nicholas AJ, University of California Executive Director. Census statistics in 2010 showed Asians to be the fastest growing racial group. U.S. Census Bureau. 2012. Published April 3, 2012. https://www.census.gov/newsroom/blogs/random-samplings/2012/04/2010-census-statistics-showed-asians-werefastest-growing-race-group.html.
Yoon M, Yang PS, Jin MN, Yu HT, Kim TH, Jang E et al. Association between physical activity level and dementia risk in a Korean national cohort. JAMA net open. 2021;4(12):e2138526.
Kim D, Yang PS, Sung JH, Jang E, Yu HT, Kim TH, et al. Reduction in dementia after catheter ablation for atrial fibrillation: a national cohort study. Eur Heart J. 2020;41(47):4483–93.
Kim D, Yang PS, You SC, Sung JH, Jang E, Yu HT, et al. Effects of treatment timing and rhythm control strategies in patients with atrial fibrillation: a national cohort study. B.M.J. 2021;373:n991.
Kim D, Yang PS, Yu HT, Kim TH, Jang E, Sung JH et al. Risk of dementia in non-stroke patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur Heart J. 2019;40(28):2313–23.
Sudlow C, Gallasher J, Allen N, Beral V, Burton P, Daensch J, et al. UK Biobank: an open-access resource for identifying the causes of a variety of complex illnesses in middle-aged and older adults. PLoS Medicine. 2015;12(3):e1001779.
Connolly JG, Gagne JJ. Caliper comparison for disease risk score matching. J Epidemiol. 2016;183(10):937–48.
Austin's PC. The optimal caliper width for propensity score matching when estimating mean differences and proportion differences in observational studies. Pharmacy Statistics 2011;10(2):150–61.
Chung MK, Refaat M, Shen WK, Kutyifa V, Cha YM, Di Biase L et al. Atrial fibrillation: JACC Council opinion. J Am Col Cardiol. 2020;75(14):1689–713.
Seshadri S, Wolf PA, Visor A, Au R, McNulty K, White R, D'Agostino RB. Lifetime Risk of Dementia and Alzheimer's Disease: The Impact of Mortality on Risk Estimates in the Framingham Study. Neurology. 1997;49(6):1498–504.
Visor A, D'Agostino RB, Sr. Seshadri S, Sullivan LM, Wolf PA. Calculating incidence estimates including lifetime risk: Alzheimer's disease in the Framingham study. Practical Incidence Estimation (PIE) Macro. statistical medicine. 2000;19(11–12):1495–522.
Fine JP, Gray RJ. Proportional hazards models for competing risk subdistributions. J Am Stat Assoc. 1999;94(446):496–509.
Grant S, Chen YQ, May S. Performance of goodness-of-fit tests for Cox proportional hazards models with time-varying covariates. Lifetime data analysis. 2014;20(3):355–68.
Huxley RR, Lopez FL, Folsom AR, Agarwal SK, Loer LR, Soliman EZ, et al. Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: Atherosclerosis risk in the community (ARIC) ) the study. Circulation. 2011;123(14):1501–8.
Norby FL, Benjamin EJ, Alonso A, Chu SS. Racial and ethnic considerations in patients with atrial fibrillation: JACC Focus Seminar 5/9. J Am Col Cardiol. 2021;78(25):2563–72.
O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional impact of potentially modifiable risk factors associated with acute stroke (INTERSTROKE) in 32 countries: a case-control study. Lancet. 2016;388(10046):761–75.
Schnabel RB, Ying X, Gona P, Larson MG, Beiser AS, McManus DD, et al. Fifty-year trends in the prevalence, incidence, risk factors, and mortality of atrial fibrillation in the Framingham Heart Study: A cohort study. Lancet. 2015;386(9989):154–62.
Zhang Z, Zhang X, Korantzopoulos P, Letsas KP, Tse G, Gong M, et al. Thiazolidinedione use and atrial fibrillation in patients with diabetes: a meta-analysis. BMC cardiovascular disorders. 2017;17(1):96.